The purpose of this first time-in-human (FTiH) study is to evaluate the safety, reactogenicity and immunogenicity of different dose levels of an experimental rabies glycoprotein G (RG) vaccine (RG-SAM [CNE] vaccine), made using a new technology, when administered intramuscularly (IM) on a 0, 2, 6 *-month schedule to healthy adults.

* There will be no vaccinations with the third dose of any of the study treatments.

Inclusion Criteria:

• Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. participation in genetics research, completion of the electronic diary cards, return for follow-up visits).

• Written informed consent obtained from the participant prior to performance of any study specific procedure.

• Healthy participants as established by medical history and clinical examination before entering into the study.

• A male or female participant between, and including, 18 and 40 years of age at the time of the first vaccination.

• Body Mass Index >18 Kg/m^2 and <35 Kg/m^2.

• Participants with following hematological/biochemical parameters:

  • White Blood Cells and differential, within the study designated laboratory normal range. Participants with FDA toxicity grade 1 differential cell counts and considered not clinically significant may be enrolled at the discretion of the investigator, and with the review and approval of the medical monitor.
  • Platelets = 125,000 - 500,000 cells/mm^3
  • Hemoglobin within normal range of the study designated laboratory
  • Alanine aminotransferase within the study designated laboratory normal range
  • Aspartate aminotransferase within the study designated laboratory normal range
  • Total bilirubin within the study designated laboratory normal range
  • Alkaline phosphatase within the study designated laboratory normal range
  • Serum creatinine less than or equal to 1.1 times study designated laboratory's upper normal limit .
  • Seronegative for hepatitis B surface antigen, hepatitis C virus antibodies, or human immunodeficiency virus antibodies

• Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.

• Female participants of childbearing potential may be enrolled in the study, if the participant

  • has practiced adequate contraception for 30 days prior to vaccination, and
  • has a negative pregnancy test on the day of vaccination, and
  • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series

Exclusion Criteria:

• History of diagnosis with rabies exposure, infection or disease.
• Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
• Family history of congenital or hereditary immunodeficiency.
• History of or current autoimmune disease.
• History of any reaction or hypersensitivity likely to be exacerbated by any components of RabAvert including polygeline, bovine gelatin, neomycin, chlortetracycline and amphotericin B, chicken protein, egg products or any other vaccine component.
• Lymphoproliferative disorder or malignancy within previous 5 years (excluding effectively treated non-melanotic skin cancer).
• Hypersensitivity to latex.
• History of Type I hypersensitivity reactions to any beta-lactam antibiotics (penicillin, aminopenicillins, cephalosporins and carbapenems).
• Any acute or chronic, clinically significant disease, as determined by physical examination, laboratory screening tests, subject personal report and/or General Physician (GP) information.
• Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before the first dose of study vaccines, or planned use during the study period.
• Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the vaccination and ending 30 days after (Influenza vaccine excluded).
• Previous vaccination with any licensed or investigational rabies vaccine.
• Administration of immunoglobulins and/or any blood products within the 3 months preceding the dose of study vaccine or planned administration during the study period.
• Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period within 6 months prior to the vaccine dose.
• Current allergy treatment with allergen immunotherapy with antigen injections, unless on maintenance schedule.
• Concomitant or planned administration of antimalarial drugs, to include hydroxychloroquine within 30 days of vaccination.
• Current anti-tuberculosis prophylaxis or therapy.
• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been/will be exposed to an investigational or a non-investigational vaccine/product.
• Pregnant or lactating female participant.
• Female participant planning to become pregnant or planning to discontinue contraceptive precautions.
• Participants at a higher risk than the average US resident with regard to exposure to rabies, per the RabAvert package insert and rabies vaccination recommendations from the Centers for Disease Control (CDC).
• Participants with extensive tattoos covering deltoid region on both the arms that would preclude the assessment of local reactogenicity.
• Planned move to a location that will prohibit participating in the trial until study end.
• Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation.

IPD for this study will be made available via the Clinical Study Data Request site.

IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an exemption can be granted, when justified, for up to another 12 months.

In Part 1 of the study, only data during the primary vaccination phase (from study start to Day 91) will be collected in an observer-blind manner. By observer-blind, it is meant that the vaccines recipient and those responsible for the evaluation of any study endpoint will all be unaware of which vaccine was administered.

For Part 1, the study will be observer-blind until Day 91. When the Day 91 analysis will result in unblinding of all the subjects to the sponsor. Therefore, the study cannot be considered observer-blind beyond Day 91 and will be conducted in a single-blind* manner thereafter; with all subjects remaining blinded up to study conclusion (Month 14).

For Part 2, the study will be conducted in open-label manner from study start to study conclusion.

*Due to the recent COVID-19 pandemic, the study will be fully unblinded from study start to study conclusion to allow all subject treatments to be known to the team and investigators, thereby facilitating rapid safety assessment.